Physician profile
Lester Labus
NPI 1235124413
$5,439.81
in general payments reported to CMS, 2019-2025
36 companies · $1,318 in 2025
The $1,318 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2020: $172 · 2021: $972 · 2022: $1,030 · 2023: $455 · 2024: $886 · 2025: $1,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,659.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,330.82 | 2019-2025 | |
| Novo Nordisk INC | $882.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $564.37 | 2020-2025 | |
| Glaxosmithkline, LLC. | $398.80 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $386.92 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $264.58 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $247.06 | 2021-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $118.31 | 2021-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $112.67 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $101.53 | 2022-2025 | Jardiance |
| Astellas Pharma US INC | $89.88 | 2023-2025 | Veozah |
| Amarin Pharma, INC. | $69.01 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $68.06 | 2024-2025 | Zenpep |
| Axsome Therapeutics, INC. | $60.38 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $60.01 | 2022-2024 | Rexulti |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $57.99 | 2019-2025 | Lagevrio, Gardasil 9, Capvaxive |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.76 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.79 | 2021-2023 | |
| Mylan Specialty L.P. | $51.00 | 2024 | Yupelri |
| Corcept Therapeutics | $50.22 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $46.19 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $40.68 | 2022-2024 | Gvoke Hypopen |
| Amgen INC. | $39.60 | 2021-2024 | Otezla, Repatha |
| Averitas Pharma INC. | $36.80 | 2023-2024 | Qutenza |
| Exact Sciences Corporation | $35.65 | 2025 | Cologuard Collection Kit |
| Convatec INC. | $31.34 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $30.89 | 2021 | |
| Valinor Pharma, LLC | $23.26 | 2025 | Movantik |
| Kyowa Kirin, INC. | $21.50 | 2024 | Crysvita |
| Daiichi Sankyo INC. | $19.72 | 2025 | Injectafer |
| Viatris Specialty LLC | $19.07 | 2025 | Yupelri |
| Sumitomo Pharma America, INC. | $16.76 | 2023 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $14.75 | 2022 | |
| Evoke Pharma, INC. | $14.11 | 2025 | |
| Athena Bioscience, LLC | $14.06 | 2024 | Nexiclon Xr |
| Biogen, INC. | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lester Labus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.